Berk, L.The management of bipolar disorder in primary care: a review of existing and emerging therapies.
Psychiatry Clin Neurosci 2005;59:229–239.
Rae, DSet al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–2518.
Portera, L.A history of substance abuse complicates remission from acute mania in bipolar disorder.
J Clin Psychiatry 1999;60:733–740.
Sonne, J.Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441–449.
Carroll, BJ.Substance abuse in bipolar disorder.
Bipolar Disord 2001;3:181–188.
Casagrande, TSet al. Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam.
Pharmacol Biochem Behav 2009;91:636–642.
Yao, JK.Free radical pathology in schizophrenia: a review.
Prostaglandins Leukot Essent Fatty Acids 1996;55:33–43.
Akyol, O.Antioxidant enzyme activities and oxidative stress in affective disorders.
Int Clin Psychopharmacol 2004;19:89–95.
Viale, CIet al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects.
Neurosci Lett 2007;421:33–36.
Rosa, ARet al. Serum S100B and antioxidant enzymes in bipolar patients.
J Psychiatr Res 2007;41:523–529.
Kunz, Met al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report.
Prog Neuropsychopharmacol Biol Psychiatry 2007;31:283–285.
Chianetta, JM.Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations.
Prog Neuropsychopharmacol Biol Psychiatry 2007;31:365–369.
Belmonte-de-Abreu, P.Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation.
Rev Bras Psiquiatr 2008;30:337–340.
Kapczinski, F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:512–515.
Andreazza, ACet al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males.
Neurosci Lett 2008;433:270–273.
O’Brien, C.Drug addiction as a pathology of staged neuroplasticity.
Renshaw, PF.Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research.
Mol Psychiatry 2005;10:900–919.
Wozniak, Aet al. Lack of changes in the concentration of thiobarbituric acid-reactive substances (TBARS) and in the activities of erythrocyte antioxidant enzymes in alcohol-dependent patients after detoxification.
Med Sci Monit 2008;14:CR32–CR36.
Lake, RWet al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse.
Nat Neuroscience 2003;6:743–749.
Seamans, JK.Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking.
J Neurosci 2005;25:6389–6393.
Kalivas, PW.Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior.
J Neurosci 2003;23:3531–3537.
Kau, KSet al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine.
J Neurosci 2007;27:13968–13976.
Kalivas, PW.N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking.
Biol Psychiatry 2008;63:338–340.
Odlaug, BL.N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.
Biol Psychiatry 2007;62:652–657.
Lauterburg, BH.Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration.
Eur J Clin Pharmacol 1989;36:127–131.
26.Holdiness, MR.Clinical pharmokinetics of N-acetylcysteine.
Clincal Pharmokinetics 1991;20:123–134.
van den Buuse, M,
Bush, AI.N-acetylcysteine treatment inhibits depletion of brain glutathione levels in rats: implications for schizophrenia. Int J Neuropsychopharmacol 2004;7:S262.
Bush, AI.N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis.
De Jong, JM.Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.
Arch Neurol 1995;52:559–564.
Brown, RH Jr,
Kuncl, RW.Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons.
Proc Natl Acad Sci U S A 1994;91:4155–4159.
Butterfield, DA.In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage.
Biochimica et Biophysica Acta 1999;1453:407–411.
Noble, M.N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro.
Proc Natl Acad Sci U S A 1994;91:7496–7500.
Herzenberg, LA.Redox regulation of activation of NF-kappa B transcription factor complex: effects of N-acetylcysteine.
Methods Enzymol 1995;252:168–174.
Greene, LA.N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells.
J Neurosci 1995;15:2857–2866.
Dean, Oet al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial.
Biol Psychiatry 2008;64:361–368.
Dean, Oet al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial.
Biol Psychiatry 2008;64:468–475.
37.Guy, W.ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.